BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Treanda regulatory update

The U.K.'s NICE issued a final appraisal determination recommending the use of Levact bendamustine from Mundipharma as a first-line treatment for patients with chronic lymphocytic leukemia (CLL) for whom fludarabine combination chemotherapy is not appropriate - its approved indication. NICE did not issue a preliminary appraisal and said it proceeded straight to the...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >